Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

(2015) Jordi Bruix et al.   LANCET ONCOLOGY

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

(2014) YU SAWADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients

(2013) Ke Pan et al.   ANNALS OF SURGICAL ONCOLOGY

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

(2013) Elise P. Salerno et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

(2013) J. Fourcade et al.   CANCER RESEARCH

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

(2013) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

(2013) Yu Sawada et al.   Human Vaccines & Immunotherapeutics

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

(2013) Shiro Suzuki et al.   Human Vaccines & Immunotherapeutics

Immunotherapy of cancer in 2012

(2012) John M. Kirkwood et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma

(2012) Eishiro Mizukoshi et al.   HEPATOLOGY

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors

(2011) Shuichiro Shiina et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells

(2011) Toshiaki Yoshikawa et al.   CANCER SCIENCE

Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

(2011) Tetsuya Nakatsura   INTERNATIONAL JOURNAL OF ONCOLOGY

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

(2009) Hirofumi Shirakawa et al.   CANCER SCIENCE

Novel advancements in the management of hepatocellular carcinoma in 2008

(2008) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY